

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

ACN

RRID:CVCL_1068

Type: Cell Line

Proper Citation

RRID:CVCL_1068

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1068

Proper Citation: RRID:CVCL_1068

Description: Cell line ACN is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Melanoma

Defining Citation: [PMID:1354203](#), [PMID:2467885](#), [PMID:8509230](#), [PMID:15150552](#), [PMID:20164919](#), [PMID:30894373](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Probably contaminated. The STR profile of ACN and LN-464 are identical. SNP analysis (DepMap) also shows identity of both cell lines. We believe this is a melanoma cell line based on the presence of the BRAF V600E mutation as well as the RNASeq expression profile of LN-464 (DepMap) which clusters with that of melanoma patient samples. Originally thought to originate from the bone marrow of a 36-month old boy with a metastatic adrenal stage-IV neuroblastoma..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ACN

Cross References: CLO:CLO_0001655, CLDB:cl239, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, cancercellines:CVCL_1068, Cell_Model_Passport:SIDM00057, ChEMBL-Cells:ChEMBL3308148, ChEMBL-Targets:ChEMBL2366195, Cosmic:906803, Cosmic-CLP:906803, DepMap:ACH-002389,

EGA:EGAS00001000978, GDSC:906803, GEO:GSM1669594, IARC_TP53:21170, ICLC:HTL96020, LINCS_LDP:LCL-1982, Pharmacodb:ACN_55_2019, PubChem_Cell_line:CVCL_1068, Wikidata:Q54608539

ID: CVCL_1068

Record Creation Time: 20220427T215127+0000

Record Last Update: 20260905T184437+0000

Ratings and Alerts

No rating or validation information has been found for ACN.

No alerts have been found for ACN.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

de Mello RS, et al. (2025) Effects of nanoflubendazole and purinergic signaling modulation in overcoming neuroblastoma chemoresistance. Purinergic signalling.

Arnaud-Sampaio VF, et al. (2022) P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma. Frontiers in oncology, 12, 966404.